Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Lenalidomide
Revlimid · 1 trial · 1 indication
Determine the maximum tolerated dose (MTD) of lenalidomide when given in combination with rituximab, Ifosfamide, etoposide, and carboplatin (RICE) for the treatment of DLBCL patients in first relapse by incidence of dose-limiting toxicity (DLT) for Stage I Patients Only
Rate of overall response by incidence of Complete Response, Partial Response, and Stable Disease per Modified International Working Group (IWG) response criteria for patients enrolled in Stage II
Rate of overall response by incidence of Complete Response, Partial Response, and Stable Disease per Modified International Working Group (IWG) response criteria for patients enrolled in Stage III
| Arm | Type | Description |
|---|---|---|
| Revlimid (Lenalidomide) in Combination | EXPERIMENTAL | Study of Lenalidomide in Combination with Rituximab, Ifosphamide, Etoposide, and Carboplatin (RICE-R) as Salvage Therapy with Single Agent Lenalidomide as Maintenance Therapy Post-Autologous Stem Cell Transplantation |
| Name | Type | Description |
|---|---|---|
| Revlimid | DRUG | Stage I: Cohort 1: RICE + Lenalidomide 10mg days 1-7 Cohort 2: RICE + Lenalidomide 15mg days 1-7 Cohort 3: RICE + Lenalidomide 20mg days 1-7 Cohort 4: RICE + Lenalidomide 25mg days 1-7 Stage II: RICE + Lenalidomide at the MTD days 1-7 Stage III: Lenalidomide 25mg days 1-21 every 28 days |
Inclusion Criteria:Understand and voluntarily sign an informed consent form. 1. Age 18 years at the time of signing the informed consent form. 2. Able to adhere to the study visit schedule and other protocol requirements. 3. Histologically confirmed diffuse large B cell lymphoma 4. Relapsed or refr...
Revlimid, also known as lenalidomide, is being studied for use in Diffuse Large B Cell Lymphoma (DLBCL). It is an investigational small molecule in Phase 1 clinical development for this indication. The drug is being evaluated in combination with RICE chemotherapy followed by lenalidomide maintenance after autologous transplant.
Revlimid targets cereblon, a protein involved in the ubiquitin-proteasome pathway. By binding to cereblon, it modulates the activity of certain transcription factors and cytokines, which can affect tumor cell growth and survival. This mechanism is being explored in the context of Diffuse Large B Cell Lymphoma.
Revlimid is being developed by Meridian Bioscience Inc, a company traded under the ticker VIVO. The drug is currently in Phase 1 clinical trials for Diffuse Large B Cell Lymphoma. Meridian Bioscience is conducting research to evaluate the safety and efficacy of this investigational therapy.
Revlimid is in Phase 1 clinical development for Diffuse Large B Cell Lymphoma. It is an investigational drug, meaning it has not been approved by regulatory authorities for this indication. The Phase 1 trial has been completed, and the drug is still in the early stages of clinical testing.
Revlimid has one completed clinical trial, NCT01241734, titled 'Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL'. This Phase 1 study enrolled 18 participants with Diffuse Large B Cell Lymphoma in the United States. The trial was uncontrolled and not randomized or double-blinded.
Yes, Revlimid is the same as lenalidomide. Lenalidomide is the generic name for the drug, while Revlimid is a brand name. In clinical trials, it is often referred to by its generic name, as seen in the study title for NCT01241734, which uses 'Lenalidomide' to describe the investigational agent.